Forward-looking Statements

This information contains forward-looking statements which may be identified by their use of words like "plans," "expects," "will," "believes," "intends," "estimates," "anticipates" or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Nexeon MedSystems Inc’s ("Nexeon") growth strategy, product development, regulatory approval, market position, anticipated benefits of acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward-looking statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company's control. Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; significant litigation and environmental matters; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, weather events and natural disasters; ability to protect and enforce the company's intellectual property rights; successful integration of acquired businesses and separation of under-performing or non-strategic assets or businesses. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.
Neurostimulation Systems are used to restore neuronal function

1. Nexeon’s SYNAPSE™ device is the platform used in a process known as Deep Brain Stimulation (DBS).

2. Platform acts like a brain pacemaker sending electrical pulses to specifically targeted locations in the brain.

3. New advances include patient specific stimulation programming and technology called Local Field Potential Recording.

4. The market for DBS devices to treat Parkinson’s disease will reach USD 3.21 Billion Globally in 2020.
The global neurostimulation market will pass $7 billion by 2020.
The Market
DBS Market Landscape

<table>
<thead>
<tr>
<th>Year</th>
<th>Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>$520</td>
</tr>
<tr>
<td>2015</td>
<td>$560</td>
</tr>
<tr>
<td>2016</td>
<td>$600</td>
</tr>
<tr>
<td>2017</td>
<td>$650</td>
</tr>
<tr>
<td>2018</td>
<td>$700</td>
</tr>
</tbody>
</table>

7-9% CAGR

DBS Market Opportunity

01 Medtronic only US approval >10M ET patients in the US

02 Lack of education primary reason for lack of scale, discussed adoption/percentage

03 Boston Scientific has captured ~30% market share from new electrode steering

04 Established reimbursement in US enables revenues in 2018 during pivotal

05 Rechargeable enables more attractive reimbursement codes in the future
SYNAPSETM
Alleviates shortcomings in today’s DBS therapy, meaning fewer compromises for patients

Benefits

- Rechargeable means more greater range of available therapies
- Rechargeable enables 1 surgery versus multiple
- Provide directional stimulation which limits side effects
- Enable the detection, measurement and collection of brain signals while simultaneously providing targeted DBS therapy
- Multiple stimulation frequencies enables increased therapy range
- IPG can interface with all approved DBS systems

Reprogramming visits are poorly reimbursed and average 24 hours per patient
Sales & Marketing Launch
2017 Plan Overview

CE Mark
Technical File

$5M in awarded non-dilutive funding

Medi-Line
Integration of manufacturing platform

DBS commercial launch Q2 2018

Positioned for revenues to grow to
~$200M in 2023 US launch

Indirect sales in Europe

PMA Pivotal Study to begin 2018
Leadership

WILL ROSELLINI
Chairman, CEO

- 6 advanced degrees related to translational medicine
- 15-yr vet in neurotech
- 3 successful exits

BRIAN BLISCHAK
President, Chief Commercial Officer

- Neuroengineer with 20 yrs in medical device field
- Successfully led 3 neurostim product launches from new product to US approval

CHRIS MILLER
CFO

- 15+ yrs serving as CFO, treasurer, and interim CFO for wide variety of early-stage & non-profit organizations, both public & private
Intellectual Property Position

- **7 Patents** Pending
- **13 Patents** Granted
- **6 Patents** Pending
- **68 Patents** Granted

- **Self-healing networks** (Siemens portfolio)
- **Remote monitoring** (Medtronic portfolio)
- **Internet of Medical Things** (Siemens portfolio)
- **Proprietary ASIC** (Synaptix acquisition)
<table>
<thead>
<tr>
<th>Shares Issued &amp; Outstanding</th>
<th>26,895,011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Options Outstanding</td>
<td>3,802,000 (@ $1.00)</td>
</tr>
<tr>
<td>Warrants</td>
<td>656,761 (@ $2.00)</td>
</tr>
<tr>
<td>Fully Diluted Shares</td>
<td>31,278,062</td>
</tr>
<tr>
<td>Float</td>
<td>~7.2M</td>
</tr>
<tr>
<td>Market Cap</td>
<td>$11,000,000</td>
</tr>
</tbody>
</table>
\textbf{Indication Expansion}

Expansive opportunity in neurostimulation with NNS platform technology

\textbf{DEEP BRAIN STIMULATION}

- Parkinson’s and Essential Tremor, CE Mark 2018
- Parkinson’s US pivotal begin Q3, 2018
  - European revenues and US revenues during pivotal study

\textbf{PERIPHERAL NERVE STIMULATION}

- Pre-submission meeting complete for second US PMA product
- Funded preclinical work in progress
- Clinical study, aVNS for relief of atrial fibrillation

\textbf{OEM BUSINESS TO EXPAND PLATFORM NEUROSTIMULATION SALES}

- Manufacturing agreement with GlaxoSmithKline for their Galvani Bioelectronics program
- Medline represents significant enhancement of supply chain efficiencies and support of second product launch
Motivation to Treat Cancer Mediated Neurogenic OAB

• Radiotherapy and surgical resection are life-saving therapies that often lead to over active bladder (OAB)
• OAB found in 30% of prostate cancer 3 years after radiation
• Case in point: Prostate cancer survivors treated by radical prostatectomy
  – OAB expected in 11% of the cases in 2014
  – UT Southwestern Medical Center Urology Clinic performs 250-300 procedures annually
• 70% of cervical cancer patients exhibit OAB symptoms following surgical treatment
• Symptoms may be a reason for patients to forego cancer therapy or pursue inferior treatments options

- Reduced Quality of Life
- Social Isolate
- Reduced Productivity
- Frequency
- >8 times/day
- Impaired Domestic Function
- Urgency
- May include Incontinence
- Low Sexual Performance
- Nocturia
- Awaking during night
- Disturbed Sleep
- Impaired Mobility
- Reduced Productivity
Sacral Nerve Stimulation (SNS) Therapy

• Over the past two decades, SNS has continued to gain popularity to relieve refractory OAB symptoms with studies demonstrating that it is an effective treatment with potentially long-term enduring benefits.

• SNS is delivered to patients characterized by severe refractory OAB symptoms or patients who are not candidates for second-line therapy and are willing to undergo a surgical procedure.

• Approximately 30,000 SNS device are implanted per year. Devices require replacement at least every 5.4 years, consequently as many as 162,000 patients are receiving SNS.
SNS Innovation at Nexeon

- Rechargeable battery
- Independent channel control
- Closed-loop system
  - Ability to record sacral nerve activity
  - Patient tailored stimulation: parameters and waveform
  - Therapy can be delivered intermittently
    - Sacral nerve activity measurements will help determine occurrence of urge, contractions, or voiding, and deliver stimulation at the appropriate time
    - Reduce stimulation-induced side effects, and potentially improve therapeutic efficacy
Clinical Strategy

Feasibility Study
• Open-label, single-center study designed to determine if recording neural activity from the sacral nerve is feasible.
• Patients scheduled to receive an SNS implant (de novo or replacement) will be consented
• Neural recording will be collected in one or more sessions
  1. Spontaneous nerve activity measurements
     A. Neural recordings will be measured with Interstim lead in
     B. Recordings will help elucidate the possible neurogenic mechanism (aberrant sacral nerve activity)
     C. De novo or replacement patients
  2. Urodynamic evaluation
     A. Neural recordings will be measured with Interstim leads during a bladder catheter fill procedure
     B. Correlate nerve activity with bladder contraction/void
     C. De novo patients only
  3. Bladder Stimulation via intraurethral catheter
     A. Neural recordings will be measured with Interstim lead during bladder stimulation procedure
     B. Specialized catheter with electrodes will stimulate the bladder neck (simulate bladder contractions)
     C. De novo patients only
Reimbursement

<table>
<thead>
<tr>
<th>CMS Coverage Decision by Technical Evaluation Centers</th>
<th>Sacral Nerve Stimulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVERED and Medically Needed, if confirmed by Test</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CMS Patient Coverage Eligibility</th>
<th>(Abstract, See details)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient must be:</td>
<td></td>
</tr>
<tr>
<td>refractory to conventional therapy and</td>
<td></td>
</tr>
<tr>
<td>be an appropriate surgical candidate.</td>
<td></td>
</tr>
<tr>
<td>Patient must have had a successful test stimulation</td>
<td></td>
</tr>
<tr>
<td>Patient must be able record voiding diary data</td>
<td></td>
</tr>
<tr>
<td>The following patients are excluded: stress incontinence, urinary obstruction, and specific neurologic diseases</td>
<td></td>
</tr>
</tbody>
</table>

- Severe Eligibility Criteria need to drive Patient Inclusion / exclusion criteria in Pilot Trials
- SNS is the ideal Benchmark